The combination of Tecvayli (teclistamab-cqyv), a bispecific T-cell engager antibody therapy, and Darzalex Faspro (daratumumab and hyaluronidase-fihj), a subcutaneous CD38-directed antibody, met the primary endpoint of progression-free survival and the results were statistically significant and superior to standard of care in relapsed/refractory multiple myeloma who received one to three prior lines of therapy, according to data from the phase III MajesTEC-3 study. This was compared to the investigator’s choice of Darzalex Faspro, pomalidomide, and dexamethasone or Darzalex Faspro, bortezomib, and dexamethasone.
Credit: Northwell Health.Northwell Health and START Center for Cancer Research have unveiled a $5.7M, 10,000 square foot early-phase cancer clinical trial center that aims to provide better access to treatments for cancer patients in New York and Long Island.
